Specify a stock or a cryptocurrency in the search bar to get a summary
Cyxone AB
CYXOCyxone AB (publ), a clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases. Its product pipeline comprises Rabeximod, which is in phase II clinical development for the treatment of rheumatoid arthritis; and T20K for the treatment of multiple sclerosis and is in phase I trial. The company was founded in 2015 and is headquartered in Malmö, Sweden. Address: Hylle Boulevard 34, Malmö, Sweden, 215 32
Analytics
WallStreet Target Price
42.7 SEKP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CYXO
Dividend Analytics CYXO
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CYXO
Stock Valuation CYXO
Financials CYXO
Results | 2019 | Dynamics |